AbbVie seeks accelerated FDA approval for teliso-V, an antibody-drug conjugate for c-Met overexpressing non-small cell lung cancer. This treatment targets a specific group of patients with a poor prognosis, lacking approved therapies. ADCs combine antibodies with toxic agents to combat cancer.